BACKGROUND. Renin, secreted into the blood by the juxtaglomerular cells of the kidneys, is derived from a larger precursor, prorenin. Plasma prorenin activity is increased in patients with insulin-dependent (Type I) diabetes mellitus who have microvascular complications of their disease. We undertook this study to determine prospectively whether rising prorenin activity can predict the development of complications in young patients with Type I diabetes. METHODS AND RESULTS. Plasma prorenin was measured in 135 children and adolescents with Type I diabetes. The mean (+/- SE) plasma prorenin activity among the 32 patients over the age of 10 years who had had uncomplicated diabetes for 0.1 to 5 years was 8.43 +/- 0.58 ng of angiotensin I per liter.second, as compared with 7.06 +/- 0.32 in 37 control subjects of the same age (P less than 0.05). In the 9 patients older than 10 who had retinopathy or overt albuminuria, the mean plasma prorenin activity was 13.09 +/- 1.43 ng of angiotensin I per liter.second (P less than 0.0001). In 34 patients 10 years old or older with uncomplicated diabetes, 3 to 13 measurements of plasma prorenin activity were taken during a follow-up period of 6 to 39 months. Urinary albumin was determined at each visit, and the patients had regular retinal examinations. Only 1 of the 20 patients who had consistently normal plasma prorenin values had overt albuminuria (ratio of urinary albumin to creatinine, greater than 0.017) or retinopathy, whereas one or both of these complications appeared in 8 of the 14 who had at least one high prorenin value. The plasma prorenin value was significantly higher in these eight patients at least 18 months before a complication was found. CONCLUSIONS. Increased plasma prorenin activity identifies a group of young patients with diabetes who are at high risk for retinopathy or nephropathy.
Source Information
Department of Pediatrics, Stanford University School of Medicine, Calif.
This article has been cited by other articles:
Advani, A., Kelly, D. J., Cox, A. J., White, K. E., Advani, S. L., Thai, K., Connelly, K. A., Yuen, D., Trogadis, J., Herzenberg, A. M., Kuliszewski, M. A., Leong-Poi, H., Gilbert, R. E.
(2009). The (Pro)Renin Receptor: Site-Specific and Functional Linkage to the Vacuolar H+-ATPase in the Kidney. Hypertension
54: 261-269
[Abstract][Full Text]
Muller, D., Muller, D. N.
(2009). Battle against the renin-angiotensin system: help from an unexpected party. Nephrol Dial Transplant
24: 1110-1112
[Full Text]
(2008). Questions & Answers -- Understanding the Renin System. Journal of Renin-Angiotensin-Aldosterone System
9: 247-249
Campbell, D. J.
(2008). Critical Review of Prorenin and (Pro)renin Receptor Research. Hypertension
51: 1259-1264
[Full Text]
Feldt, S., Maschke, U., Dechend, R., Luft, F. C., Muller, D. N.
(2008). The Putative (Pro)renin Receptor Blocker HRP Fails to Prevent (Pro)renin Signaling. J. Am. Soc. Nephrol.
19: 743-748
[Abstract][Full Text]
Feldt, S., Batenburg, W. W., Mazak, I., Maschke, U., Wellner, M., Kvakan, H., Dechend, R., Fiebeler, A., Burckle, C., Contrepas, A., Jan Danser, A.H., Bader, M., Nguyen, G., Luft, F. C., Muller, D. N.
(2008). Prorenin and Renin-Induced Extracellular Signal-Regulated Kinase 1/2 Activation in Monocytes Is Not Blocked by Aliskiren or the Handle-Region Peptide. Hypertension
51: 682-688
[Abstract][Full Text]
Muller, D. N., Klanke, B., Feldt, S., Cordasic, N., Hartner, A., Schmieder, R. E., Luft, F. C., Hilgers, K. F.
(2008). (Pro)Renin Receptor Peptide Inhibitor "Handle-Region" Peptide Does Not Affect Hypertensive Nephrosclerosis in Goldblatt Rats. Hypertension
51: 676-681
[Abstract][Full Text]
Stankovic, A. R., Fisher, N. D.L., Hollenberg, N. K.
(2006). Prorenin and Angiotensin-Dependent Renal Vasoconstriction in Type 1 and Type 2 Diabetes. J. Am. Soc. Nephrol.
17: 3293-3299
[Abstract][Full Text]
Hollenberg, N. K
(2005). Spotlight on Renin: Therapeutic opportunities for renin inhibitors. Journal of Renin-Angiotensin-Aldosterone System
6: 107-109
Williams, K. J., Liu, M.-L., Zhu, Y., Xu, X., Davidson, W. R., McCue, P., Sharma, K.
(2005). Loss of Heparan N-Sulfotransferase in Diabetic Liver: Role of Angiotensin II. Diabetes
54: 1116-1122
[Abstract][Full Text]
Fisher, N. D.L., Hollenberg, N. K.
(2005). Renin Inhibition: What Are the Therapeutic Opportunities?. J. Am. Soc. Nephrol.
16: 592-599
[Abstract][Full Text]
Strain, W D., Chaturvedi, N.
(2002). Review: The renin-angiotensin-aldosterone system and the eye in diabetes. Journal of Renin-Angiotensin-Aldosterone System
3: 243-246
[Abstract]
Mauer, M., Zinman, B., Gardiner, R., Drummond, K. N, Suissa, S., Donnelly, S. M, Strand, T. D, Kramer, M. S, Klein, R., Sinaiko, A. R
(2002). ACE-I and ARBs in early diabetic nephropathy. Journal of Renin-Angiotensin-Aldosterone System
3: 262-269
[Abstract]
Muller, D. N., Hilgers, K. F., Mathews, S., Breu, V., Fischli, W., Uhlmann, R., Luft, F. C.
(1999). Effects of Human Prorenin in Rats Transgenic for Human Angiotensinogen. Hypertension
33: 312-317
[Abstract][Full Text]
Mäkimattila, S., Summanen, P., Matinlauri, I., Mäntysaari, M., Schlenzka, A., Aalto, M., Irjala, K., Yki-Järvinen, H.
(1998). Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM. Br J Ophthalmol
82: 939-944
[Abstract][Full Text]
Williams, B., Baker, A. Q., Gallacher, B., Lodwick, D.
(1995). Angiotensin II Increases Vascular Permeability Factor Gene Expression by Human Vascular Smooth Muscle Cells. Hypertension
25: 913-917
[Abstract][Full Text]
Previous
